Vanessa Sarah Arciero

Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time

Ronak Saluja, Vanessa Sarah Arciero, Sierra Cheng et al. · Journal of Oncology Practice · 2018 · 88 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?

Sierra Cheng, Erica McDonald, Matthew C. Cheung et al. · Journal of Clinical Oncology · 2017 · 62 citations

Pharmacy, Oncology, Comparative Effectiveness Research +14

<p>Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome</p>

Sierra Cheng, Vanessa Sarah Arciero, Hanan Goldberg et al. · Cancer Management and Research · 2019 · 21 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group

Wei Fang Dai, Vanessa Sarah Arciero, Erica H. Craig et al. · Current Oncology · 2021 · 14 citations · Full text

Pharmacy, Health Policy, Oncology +17

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer

Vanessa Sarah Arciero, Jin Jun Luo, Ambica Parmar et al. · JNCI Cancer Spectrum · 2022 · 11 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +15